Genprex up on securing approval for dose escalation in lung cancer drug trial

Genprex

14/12/2022 18:25

** Drug developer Genprex Inc's shares  GNPX.O  rise 3.3% to
$1.20 
    ** Safety Review Committee approves continuation of the
third and final cohort in the dose escalation portion of
early-stage trial testing co's drug candidate, Reqorsa
    ** The trial is evaluating GNPX's drug in combination with
AstraZeneca Plc's  AZN.L  Tagrisso for treating late-stage
non-small cell lung cancer 
    ** U.S. FDA granted "Fast Track" designation to the
combination therapy in early January 
    ** Including session's gain, stock down 9.8% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))